PL376924A1 - Związki pirymidynowe o działaniu przeciwproliferacyjnym (II) - Google Patents

Związki pirymidynowe o działaniu przeciwproliferacyjnym (II)

Info

Publication number
PL376924A1
PL376924A1 PL376924A PL37692403A PL376924A1 PL 376924 A1 PL376924 A1 PL 376924A1 PL 376924 A PL376924 A PL 376924A PL 37692403 A PL37692403 A PL 37692403A PL 376924 A1 PL376924 A1 PL 376924A1
Authority
PL
Poland
Prior art keywords
antiproliferative activity
pyrimido compounds
pyrimido
compounds
antiproliferative
Prior art date
Application number
PL376924A
Other languages
English (en)
Inventor
Kin-Chun Luk
Pamela Loreen Rossman
Stefan Scheiblich
Sung-Sau So
Original Assignee
F.Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F.Hoffmann-La Roche Ag filed Critical F.Hoffmann-La Roche Ag
Publication of PL376924A1 publication Critical patent/PL376924A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL376924A 2002-11-04 2003-10-27 Związki pirymidynowe o działaniu przeciwproliferacyjnym (II) PL376924A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42367002P 2002-11-04 2002-11-04

Publications (1)

Publication Number Publication Date
PL376924A1 true PL376924A1 (pl) 2006-01-09

Family

ID=32312700

Family Applications (2)

Application Number Title Priority Date Filing Date
PL376916A PL376916A1 (pl) 2002-11-04 2003-10-27 Pochodne pirymido [4,5-d] pirymidyny o działaniu przeciwrakowym
PL376924A PL376924A1 (pl) 2002-11-04 2003-10-27 Związki pirymidynowe o działaniu przeciwproliferacyjnym (II)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL376916A PL376916A1 (pl) 2002-11-04 2003-10-27 Pochodne pirymido [4,5-d] pirymidyny o działaniu przeciwrakowym

Country Status (16)

Country Link
US (2) US7112676B2 (pl)
EP (2) EP1560829B1 (pl)
JP (2) JP2006513999A (pl)
KR (4) KR100763299B1 (pl)
CN (2) CN100420688C (pl)
AR (2) AR041739A1 (pl)
AT (2) ATE386744T1 (pl)
AU (1) AU2003276190A1 (pl)
BR (2) BR0315912A (pl)
CA (2) CA2502182A1 (pl)
DE (2) DE60318888T2 (pl)
ES (2) ES2298622T3 (pl)
MX (2) MXPA05004756A (pl)
PL (2) PL376916A1 (pl)
RU (2) RU2326882C2 (pl)
WO (2) WO2004041822A1 (pl)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003903501A0 (en) * 2003-07-07 2003-07-24 Commonwealth Scientific And Industrial Research Organisation A method of forming a reflective authentication device
WO2005011597A2 (en) * 2003-07-29 2005-02-10 Irm Llc Compounds and compositions as protein kinase inhibitors
FR2873127B1 (fr) 2004-07-13 2008-08-29 Omya Development Ag Procede de fabrication de particules pigmentaires autoliantes, seches ou en suspension ou dispersion aqueuses, contenant des matieres inorganiques et des liants
AU2005279337A1 (en) * 2004-08-31 2006-03-09 F. Hoffmann-La Roche Ag Amide derivatives of 7-amino-3-phenyl-dihydropyrimido [4,5-d]pyrimidinones, their manufacture and use as pharmaceutical agents
JP2008510690A (ja) * 2004-08-31 2008-04-10 エフ．ホフマン−ラ ロシュ アーゲー ３−フェニル−ジヒドロピリミド［４，５−ｄ］ピリミジノンのアミド誘導体、これらの製造、及び医薬品としての使用
JP5191391B2 (ja) * 2005-11-01 2013-05-08 ターゲジェン インコーポレーティッド キナーゼのビ−アリールメタ−ピリミジン阻害剤
ES2329419T3 (es) 2006-01-31 2009-11-25 F. Hoffmann-La Roche Ag 7h-pirido(3,4-d)pirimidin-8-onas, su preparacion y uso como inhibidores de proteinas cinasas.
US7820826B2 (en) * 2006-03-29 2010-10-26 North Carolina State University Synthesis and regioselective substitution of 6-halo-and 6-alkoxy nicotine derivatives
MX2008014618A (es) * 2006-05-15 2008-11-28 Irm Llc Composiciones y metodos para inhibidores de cinasas del receptor fgf.
US7897762B2 (en) * 2006-09-14 2011-03-01 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of proliferative diseases
CA2729045A1 (en) * 2008-07-31 2010-02-04 Philippe Bergeron Pyrimidine compounds, compositions and methods of use
JP5450632B2 (ja) 2008-09-25 2014-03-26 エフ．ホフマン−ラ ロシュ アーゲー ３−アミノ−インダゾール又は３−アミノ−４，５，６，７−テトラヒドロインダゾール誘導体
AU2009325400A1 (en) 2008-12-12 2010-06-17 Msd K.K. Dihydropyrimidopyrimidine derivatives
AU2009325398A1 (en) 2008-12-12 2010-06-17 Msd K.K. Dihydropyrimidopyrimidine derivative
HUP0800768A2 (en) 2008-12-18 2012-08-28 Bioblocks Magyarorszag Gyogyszerkemiai Es Fejlesztoe Kft 1,3-heterocycles condensed with monoterpene skeleton, their use and pharmaceutical compositions comprising such compounds
WO2010099139A2 (en) 2009-02-25 2010-09-02 Osi Pharmaceuticals, Inc. Combination anti-cancer therapy
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099363A1 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099364A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US20100318651A1 (en) * 2009-06-10 2010-12-16 Everis, Inc. Network Communication System With Monitoring
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
GB201204384D0 (en) 2012-03-13 2012-04-25 Univ Dundee Anti-flammatory agents
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
RS58514B1 (sr) 2012-06-13 2019-04-30 Incyte Holdings Corp Supstituisana triciklična jedinjenja kao inhibitori fgfr
JP6280546B2 (ja) 2012-06-26 2018-02-14 デル マー ファーマシューティカルズ ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
CN105307657B (zh) 2013-03-15 2020-07-10 西建卡尔有限责任公司 杂芳基化合物和其用途
EP3943087A1 (en) 2013-03-15 2022-01-26 Celgene CAR LLC Heteroaryl compounds and uses thereof
US9321786B2 (en) 2013-03-15 2016-04-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
PH12015502383B1 (en) 2013-04-19 2023-02-03 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
US9783504B2 (en) * 2013-07-09 2017-10-10 Dana-Farber Cancer Institute, Inc. Kinase inhibitors for the treatment of disease
AU2015292818B2 (en) 2014-07-21 2020-01-16 Dana-Farber Cancer Institute, Inc. Imidazolyl kinase inhibitors and uses thereof
US10457691B2 (en) 2014-07-21 2019-10-29 Dana-Farber Cancer Institute, Inc. Macrocyclic kinase inhibitors and uses thereof
CA2955082A1 (en) 2014-08-08 2016-02-11 Dana-Farber Cancer Institute, Inc. Uses of salt-inducible kinase (sik) inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
TWI712601B (zh) 2015-02-20 2020-12-11 美商英塞特公司 作為fgfr抑制劑之雙環雜環
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2018009544A1 (en) * 2016-07-05 2018-01-11 The Broad Institute, Inc. Bicyclic urea kinase inhibitors and uses thereof
US11241435B2 (en) 2016-09-16 2022-02-08 The General Hospital Corporation Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis
AU2018226771B2 (en) * 2017-02-28 2023-11-23 Dana-Farber Cancer Institute, Inc. Uses of pyrimidopyrimidinones as SIK inhibitors
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
AU2019262579B2 (en) 2018-05-04 2024-09-12 Incyte Corporation Salts of an FGFR inhibitor
HRP20241288T1 (hr) 2018-05-04 2024-12-06 Incyte Corporation Čvrsti oblici fgfr inhibitora i postupci za njihovu proizvodnju
EA202191800A1 (ru) * 2018-12-27 2021-09-13 Ле Лаборатуар Сервье Сас Азагетеробициклические ингибиторы мат2а и способы их применения для нацеливания на рак
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CA3157361A1 (en) 2019-10-14 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
GB201915828D0 (en) 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
JP7832891B2 (ja) 2019-12-04 2026-03-18 インサイト・コーポレイション Ｆｇｆｒ阻害剤の誘導体
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2022221170A1 (en) 2021-04-12 2022-10-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
CA3220155A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2949466A (en) 1958-03-04 1960-08-16 Parke Davis & Co Pyrimidine compounds and means of producing the same
NL6704601A (pl) 1966-04-06 1967-10-09
US4425346A (en) 1980-08-01 1984-01-10 Smith And Nephew Associated Companies Limited Pharmaceutical compositions
JPS60226882A (ja) 1984-04-24 1985-11-12 Nippon Zoki Pharmaceut Co Ltd 新規ピリミドピリミジン誘導体
US5654307A (en) * 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
WO1998024432A2 (en) 1996-12-05 1998-06-11 Sugen, Inc. Use of indolinone compounds as modulators of protein kinases
KR200143829Y1 (ko) * 1996-12-30 1999-06-15 양재신 연료펌프 교환시 연료의 비산 방지구
TR200003429T2 (tr) 1998-05-26 2001-07-23 Warner-Lambert Company Hücresel çoğalma inhibitörleri olarak bisiklik pirimidinler ve bisiklik 3,4-dihidropirimidinler.
HK1041483B (zh) 1998-10-23 2004-12-24 霍夫曼-拉罗奇有限公司 雙環氮雜環
CZ20021743A3 (cs) 1999-10-21 2002-08-14 F. Hoffmann-La Roche Ag Bicyklické dusíkové heterocykly substituované alkylaminoskupinou jako inhibitory P38 proteinkinázy
AU776250B2 (en) 1999-10-21 2004-09-02 F. Hoffmann-La Roche Ag Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of P38 protein kinase
AR030053A1 (es) 2000-03-02 2003-08-13 Smithkline Beecham Corp 1h-pirimido [4,5-d] pirimidin-2-onas y sales, composiciones farmaceuticas, uso para la fabricacion de un medicamento y procedimiento para producirlas
CA2420286A1 (en) 2000-08-31 2002-03-07 F. Hoffmann-La Roche Ag 7-oxo pyridopyrimidines as inhibitors of a cellular proliferation
MXPA04005939A (es) 2002-01-22 2005-01-25 Warner Lambert Co 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas.
US7196090B2 (en) 2002-07-25 2007-03-27 Warner-Lambert Company Kinase inhibitors
WO2004041285A1 (en) 2002-10-31 2004-05-21 Amgen Inc. Antiinflammation agents

Also Published As

Publication number Publication date
BR0315912A (pt) 2005-09-13
KR20050074540A (ko) 2005-07-18
WO2004041821A1 (en) 2004-05-21
EP1560832A1 (en) 2005-08-10
DE60319260D1 (de) 2008-04-03
CA2502180A1 (en) 2004-05-21
ATE386744T1 (de) 2008-03-15
MXPA05004757A (es) 2005-08-02
KR100774230B1 (ko) 2007-11-07
JP2006507292A (ja) 2006-03-02
AR041738A1 (es) 2005-05-26
WO2004041822A1 (en) 2004-05-21
US7129351B2 (en) 2006-10-31
AU2003276190A1 (en) 2004-06-07
AU2003274086A1 (en) 2004-06-07
ES2298622T3 (es) 2008-05-16
CN1711266A (zh) 2005-12-21
US7112676B2 (en) 2006-09-26
CA2502182A1 (en) 2004-05-21
PL376916A1 (pl) 2006-01-09
KR100774231B1 (ko) 2007-11-07
BR0316001A (pt) 2005-09-13
US20040110773A1 (en) 2004-06-10
RU2331641C2 (ru) 2008-08-20
KR20050074534A (ko) 2005-07-18
MXPA05004756A (es) 2005-08-02
AU2003274086B2 (en) 2008-07-10
KR100763299B1 (ko) 2007-10-04
EP1560832B1 (en) 2008-01-23
DE60318888T2 (de) 2009-01-08
ES2300609T3 (es) 2008-06-16
EP1560829A1 (en) 2005-08-10
US20050075272A1 (en) 2005-04-07
RU2005117341A (ru) 2006-03-10
DE60318888D1 (de) 2008-03-13
ATE384725T1 (de) 2008-02-15
DE60319260T2 (de) 2009-03-05
RU2326882C2 (ru) 2008-06-20
EP1560829B1 (en) 2008-02-20
JP2006513999A (ja) 2006-04-27
CN100420688C (zh) 2008-09-24
KR100763300B1 (ko) 2007-10-04
RU2005117340A (ru) 2006-02-27
CN1711264A (zh) 2005-12-21
AR041739A1 (es) 2005-05-26
KR20070087657A (ko) 2007-08-28
KR20070087689A (ko) 2007-08-28

Similar Documents

Publication Publication Date Title
PL376924A1 (pl) Związki pirymidynowe o działaniu przeciwproliferacyjnym (II)
PL375588A1 (pl) Związki pirymidynowe o działaniu przeciwproliferacyjnym
PT1583763E (pt) Derivados de benzoazolilpiperazina com actividade antagonista de vr1
AU2003290606A8 (en) Modular cargo carrier assembly
EP1558585A4 (en) NEUROLOGICALLY ACTIVE COMPOUNDS
GB0209022D0 (en) Compounds
EP1569644A4 (en) INDOLIZINE COMPOUNDS
GB0200283D0 (en) Compounds
AU2003297712A8 (en) Grouser assembly
PL372989A1 (pl) Triazolopirymidyny
AU2003216859A8 (en) Amidoacetonitrile compounds
AU2003231280A8 (en) Modular carwash assembly
AU2003226725A8 (en) Pyrazolopyrimidine derivatives
DE60326941D1 (en) Rs
AU2003299043A8 (en) Unloading assembly
GB0203778D0 (en) Compounds
GB0206280D0 (en) Planograms
AU2003275480A8 (en) Compounds
AU2003225816A8 (en) Activity detector circuit
AU2003225825A8 (en) Activity detector circuit
GB0203811D0 (en) Compounds
GB0207270D0 (en) Compounds
MY144310A (en) 3-cyano-quinoline deriatives with antiproliferative activity
TJ431B (en) 2-Brom-7-methil-5-oxo-5h-1,3,4-thyodyazol-(3,2-a)pyrimidin, has antibacterial activity
GB0209178D0 (en) Bed assembly

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)